Alx Oncology Holdings Inc

NASDAQ:ALXO  
60.05
+0.11 (+0.18%)
Products

ALX Oncology Announces New Data From Phase 1B Study Of ALX148

Published: 07/03/2021 11:21 GMT
Alx Oncology Holdings Inc (ALXO) - Alx Oncology Announces New Data From Aspen-01, the Phase 1b Study of Alx148, Showing Robust Objective Response in Patients With Gastric Or Gastroesophageal Junction Cancer.
Orr of 72% Observed in Patients With >2l Her2 Positive Gastric Or Gastroesophageal Junction Cancer.
Estimated Os at 12 Months of 76% for Investigational Drug.